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Abstract 
A lack of understanding of human biology creates a hurdle for the development of precision 
medicines. To overcome this hurdle we need to better understand the potential synergy 
between a given investigational treatment (vs. placebo or active control) and various 
demographic or genetic factors, disease history and severity, etc., with the goal of identifying 
those patients at increased “risk” of exhibiting clinically meaningful treatment benefit. For this 
reason, we propose the VG method, which combines the idea of an individual treatment effect 
(ITE) from Virtual Twins (Foster, et al., 2011) with the unbiased variable selection and cutoff 
value determination algorithm from GUIDE (Loh, et al., 2015). Simulation results show the VG 
method has less variable selection bias than Virtual Twins and higher statistical power than 
GUIDE Interaction in the presence of prognostic variables with strong treatment effects. Type I 
error and predictive performance of Virtual Twins, GUIDE and VG are compared through the 
use of simulation studies. Results obtained after retrospectively applying VG to data from an 
Alzheimer’s disease clinical trial also are discussed. 
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Introduction 
The concepts of personalized medicine and precision medicine have “evolved” over time, with 
precision medicine now viewed as an approach that allows for the treatment of patients while 
taking their personal signatures, such as genes, environment and lifestyles, into consideration 
in order to maximize the benefit (efficacy) and/or minimize the risk (safety) they receive from 
the treatment. In other words, treatment effects are often heterogeneous in a given patient 
population. Thus, it is necessary to improve our understanding of differential treatment effects 
observed in patients with different signatures. 
Although it is difficult to accurately assess and maximize the treatment effect for every patient, 
it may be possible to categorize patients into subgroups according to some known and pre-
defined signatures, for example, demographics, biomarkers and lab values and then assess the 
treatment effect for those subgroups. The subgroup in which the “best” treatment effect can 
be observed also could be identified via complicated statistical methods without predefining 
the variables to be used in the analysis. In this paper, we focus on the latter approach, also 
known as retrospective (or ad hoc) subgroup identification. Retrospective subgroup 
identification is a critical approach used to develop precision medicines. 
Many subgroup identification methods have been developed. For example, Negassa et al. 
(Negassa, et al., 2005) developed RECPAM which attempts to maximize the Cox partial 
likelihood. Su et al. (Su, et al., 2009) (Su, et al., 2008) developed Interaction trees (IT), which 
attempts to minimize the p-value for testing the significance of the interaction term between 
the subgroup indicator and the treatment. Foster et al. (Foster, et al., 2011) developed Virtual 
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twins (VT) which uses random forests to predict the treatment effect for each patient and then 
applies Classification and Regression Trees (CART) to identify potential subgroups. Lipkovich et 
al. (Lipkovich, et al., 2011) developed the Subgroup Identification based on Differential Effect 
Search (SIDES), which targets on the treatment effect difference but may lead to selection bias 
associated with variables having more possible cut-off values. Dusseldorp and Van Mechelen 
(Dusseldorp & Mechelen, 2014) developed QUalitative INteraction Trees (QUINT) that attempts 
to optimize a weighted sum of measures of effect size and subgroup size. Loh et al. (Loh, 2002) 
developed a method called Generalized, Unbiased, Interaction Detection and Estimation 
(GUIDE) that is a multi-purpose machine learning algorithm for constructing classification and 
regression trees. Also, Loh et al (Loh, et al., 2015) later developed a new method called GUIDE-
Interaction (Gi), which was based on the original GUIDE but targeted on the treatment effect 
difference. Also, Gi has been compared to other methods regarding the statistical properties in 
certain scenarios. The results showed that Gi was a preferred solution when the goal is to find 
the signature based on treatment difference.   
In precision medicine, the treatment effect difference forms the basis for subgroup 
identification. Most of the existing methods can identify subgroups, and some of the methods 
can obtain unbiased signature selection. However, only a few of these methods can target 
directly on the treatment effect difference, especially the individual treatment effect (ITE) 
difference, which in general is the benefit obtained from receiving treatment compared to the 
benefit obtained from receiving placebo for a particular patient.  
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During our review of the existing methods, we found that the variable selection process of Gi is 
partly driven by how well a variable predicts the response variable. Thus, in a case of a strong 
prognostic effect, Gi may select prognostic variables more often than predictive variables, since 
prognostic variables may in fact predict the response variable better than predictive variables. 
In contrast, VT directly targets on the treatment effect difference and may have better variable 
selection performance than Gi in the scenario of a strong prognostic effect. However, CART is 
implemented in the variable selection step of VT and may lead to bias in variable selection (Loh, 
et al., 2015).  
In this paper, we propose VG, a novel method that targets directly on individual treatment 
effects using an unbiased variable selection procedure by combining two methods, VT and 
GUIDE. In VG, the CART part in VT is replaced by GUIDE. The performance of VG, VT and Gi will 
be compared via simulations and a case study will be presented. 
Methods 
The VG method contains two steps: (1) estimate the individual treatment effect (ITE) difference 
using Virtual Twins; and (2) identify potential subgroup(s) using GUIDE. Benefits inherited from 
GUIDE include the ability to utilize missing covariate information and simultaneously model 
multiple endpoints.  
Without loss of generality, we illustrate the VG method for the case of binary response variable. 
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Step I. 
The first step is to estimate the ITE difference by using Random Forests (Foster, et al., 2011). Let 
Y𝑛  and T𝑛  represent the original response variable (continuous or binary) and treatment 
variable (0 = placebo; 1 = investigational treatment), respectively; and let 𝑋𝑛,𝑝 represents the 
matrix that contains all the covariates, where n is the sample size, and p is the number of 
covariates.  
Let T’𝑛  represent the flipped (or opposite) treatment variable, where T’𝑛  = 1𝑛 −  T𝑛 . The 
purpose of doing this is to estimate the counterfactual response of each patient, in other words, 
the response of a patient under the treatment that was not received.  
Let Y′𝑛 represent the estimated counterfactual response given T’𝑛 and 𝑋𝑛,𝑝. In the VG method, 
GUIDE is used to provide nonparametric estimation of  Y′𝑛. In order to do that, similar to Foster 
et al. [reference], we utilize two additional matrices that contain all possible two-way 
interactions between (a) T𝑛 and X𝑛,𝑝 and (b) T′𝑛 and X𝑛,𝑝, respectively.  
As a consequence, data used for predicting Y′𝑛  have the structure provided below, which 
contains five components and a total sample size of 2n: 
Y2𝑛
∗ = (
Y𝑛
Y′𝑛
) , T2𝑛
∗ = (
T𝑛
T′𝑛
) ,   𝑋2𝑛,𝑝
∗ = (
X𝑛,𝑝
X𝑛,𝑝
) , XT2𝑛,𝑝 =  (
T𝑛X𝑛,𝑝
T′𝑛X𝑛,𝑝
) ,
X(1 − T)2𝑛,𝑝 =  (
(1𝑛 − T𝑛)X𝑛,𝑝
(1𝑛 − T′𝑛)X𝑛,𝑝
) 
The terms T𝑛X𝑛,𝑝, T′𝑛X𝑛,𝑝, (1𝑛 − T𝑛)X𝑛,𝑝  and (1𝑛 − T′𝑛)X𝑛,𝑝represent interactions between 
the treatment indicator, flipped treatment indicator and the covariates. Note that Y′𝑛  is 
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unknown but can be predicted using GUIDE with a weight variable, which assigns 0 weight to Y𝑛 
and 1𝑛 weight to Y′𝑛 .  
After Y′𝑛  is predicted, we can calculate the individual treatment effect (ITE) difference. Let’s 
assume the ith patient with individual covariates Xi received treatment (ti= 1) and obtained 
outcome yi, and the j
th patient with individual covariates Xj received placebo (tj= 0) obtained 
outcome yj. By predicting Y′𝑛 , we have now obtained the ‘flipped’ outcome for patients i and j, 
y′i and y′j, given their individual covariates Xi and Xj, respectively. Thus, the ITE difference for 
the ith patient can be calculated as ITEi = yi −  y′i; while the ITE difference for the j
th patient 
can be calculated as ITEj = y′j −  yj. By doing this, we obtain the vector of length n containing 
the ITE differences for all the patients, conditional on their individual covariates.  
Step II. 
The goal of Step II is to identify treatment effect heterogeneity based on the estimated ITE in 
Step I.GUIDE is used to identify treatment effect patterns because of its reliable and robust 
performance in pattern recognition (Loh, 2002).  
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Figure 1. A flow chart of the GUIDE pattern recognition algorithm in the setting of finding 
heterogeneous patterns of ITE 
 
*: The starting point of the procedure 
Figure 1 shows the procedures of GUIDE, in which ITE is the outcome, Xk is the k
th covariate, p is 
the total number of covariates. Xs is the covariate that has the smallest p-value from fitting the 
univariate models ITE ~ XkI k = 1, …, p. ITEs(a), ITEs(b), Xs(a) and Xs(b) are the outcomes and 
covariate Xs that were split by value xs, respectively. SSE(a) and SSE(b) are the two SSEs 
obtained from two model fittings of ITEs(a), ITEs(b), Xs(a) and Xs(b) (Loh, 2002). Once GUIDE has 
identified the subgroups, the mean ITE difference for each subgroup is calculated. According to 
*Fit ITE ~ Xk , k = 1, .., 
p, and obtain p-
values of Goodness 
Of Fit test 
Select Xs that has the 
smallest p-value 
Split data ITE by each 
unique value of Xs, 
obtain ITEs(a), Xs(a) 
and ITEs(b), Xs(b) 
Fit ITEs(a)~Xs(a),  
ITEs(b) ~ Xs(b), 
 obtain total  
SSE = SSE(a) + SSE(b) 
Select the value of Xs, 
through which the 
total SSE is minimized 
Split the data by the 
selected value of Xs 
and then go to the 
next node 
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the algorithm, we can interpret the mean ITE difference as the difference between the 
outcome if the patient received treatment and the outcome if the patient received placebo, 
while adjusting for all the patient’s covariates.  When the original outcome variable Y is binary 
(0 or 1), the above algorithm is used to predict the probability of Y = 1, which will be ITE. And 
thus the interpretation of ITE difference would be in terms of the difference of two probabilities: 
probability of Y = 1 if the patient received treatment and probability of Y = 1 if the patient 
received placebo.  
Simulations 
Set-up 
In order to evaluate the statistical properties of the VG method and to compare it to other 
methods, we performed a simulation study.  
The targeted subgroup is the one with the corresponding signature(s) decided by the predictive 
variable interacting with the treatment variable. In other words, the treatment effect observed 
in the targeted subgroup is larger than that observed outside the targeted subgroup due to the 
interaction between the predictive variable and the treatment variable.  
Thus, we first defined the true subgroup in our simulation. The signature was decided through 
predictive variable(s). To simplify, we considered cases where there was only one predictive 
variable, Xpred, in our simulation. Moreover, we defined one prognostic variable, Xprog, which 
had only main effect to the outcome but no interaction with the treatment.  
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We defined T as the treatment variable and Y as the outcome variable. In addition, we created 
Zn,p, a matrix containing p variables that are independent with the response and treatment 
variables.  
In our simulation, we used the following models to generate the treatment vector and a 
covariate matrix: 
T (0 or 1) ~ BIN(n, 0.5)  
𝐗𝐧,𝐩+𝟐 =  (
𝑥pred,1 𝑥prog,1
⋮ ⋮
𝑥pred,n 𝑥prog,n
    𝐙𝐧,𝐩) ~ MVN(0, Ʃp+2,p+2) if all 𝐗𝐧,𝐩+𝟐 are continuous and  
Ʃ𝑝+2,𝑝+2 = (
1 0.5 ⋯ 0.5
0.5 1 ⋯ 0.5
⋮ ⋮ ⋱ ⋮
0.5 ⋯ 0.5 1
) 
For the case where we simulated binary X for Xpred, Xprog and/or Zn,p, we first simulated  
𝑝𝑥~Beta(2, 3) 
and we used 
𝑋~BIN(n, 𝑝𝑥) 
to generate the values for binary covariates. And for outcome variable Y, we used the following 
models: 
when Y is continuous:  
Y =  βpred × I(Xpred > 𝑥0) × T + βprog × Xprog +  βtrt × T +  e 
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e ~ N(0, 0.25) 
when Y is binary: 
μ =  βpred × I(Xpred > 𝑥0) × T + βprog × Xprog +  βtrt × T 
py =
exp (μ)
1 + exp (μ)
 
Y ~ BIN(n, py) 
Where 𝑥0 is the cut-off point, in our simulation, we defined 𝑥0 as the mean of Xpred and 𝑒 is the 
noise that follows a normal distribution with mean 0 and variance 0.25. We’d like to simulate a 
dataset close to that from an observed clinical trial. Since we utilize a clinical trial with 
approximately 15 covariates, and 400 subjects, the resulting simulated datasets additionally 
contained 13 noise variables (p = 13), and 400 subjects (n = 400) within each of the iterations.  
Therefore, the dataset contains all the components below: 
Y = (
𝑦1
⋮
y400
)  T = (
𝑡1
⋮
𝑡400
)  𝐗 =  (
𝑥pred,1 𝑥prog,1
⋮ ⋮
𝑥pred,400 𝑥prog,400
    𝐙𝐧,𝐩) 
To simulate different scenarios, we selected different values for βpred, βprog and βtrt. The 
different scenarios that we have simulated are summarized in Table 1.  
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Table 1.  Simulation Scenarios 
Scenarios 𝛃𝐩𝐫𝐞𝐝 𝐗𝐩𝐫𝐞𝐝 𝛃𝐩𝐫𝐨𝐠 𝐗𝐩𝐫𝐨𝐠 𝛃𝐭𝐫𝐭 
Noise 
Variables  
(p = 13) 
No 
Prognostic 
0.5 Continuous 0 None 0.2 Continuous 
No 
Prognostic 
Mix 
0.2 Binary 0 None 0.2 
Binary/ 
Continuous* 
Prognostic 0.5 Continuous 0.5 Continuous 0.2 Continuous 
*Includes 1 binary variable and 12 continuous variables. 
 
Through the three scenarios defined above, we used the following metrics to compare VG, Gi 
and VT methods:  
1) Type I error: probability of identifying a subgroup when there are no subgroups. 
2) Power: probability of identifying a subgroup when there is a subgroup. 
3) Conditional true discovery rate: conditional probability of correctly identifying the 
predictive variable when a subgroup is identified. 
For the purpose of fair comparison, we compared the power and true discovery rate for the 
three methods under the same type I error rate. We have simulated 500 iterations for each of 
the scenarios.  
Results 
According to the simulation results (Figure 2), all three methods behave similarly and 
demonstrate above 90% power and almost 100% conditional true discovery rate under most of 
Type I error rates when the predictive variable was continuous and there was no prognostic 
effect.  
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In the scenario where the predictive variable was binary with an effect size of 0.2 and one of 
the noise covariates was also binary, Gi demonstrated higher power and conditional true 
discovery rate than the other two methods, especially when the Type I error was controlled 
between 0 and 0.4.  
When the prognostic effect was added to the simulation as a continuous variable, Gi had lower 
power and similar or lower conditional true discovery rate compared to the other two methods. 
Since the VG and VT methods are very similar with respect to the background framework, these 
two methods behave very much alike. However, one can still notice about 5% improvement 
with VG compared to VT in the simulation results regarding the conditional true discovery rate, 
especially in the ‘Prognostic’ scenario.  
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Figure 2. Plot of Power (Left) and Conditional True Discovery Rate (Right) vs Type I error 
No prognostic scenario 
 
 
No prognostic Mix scenario 
  
Prognostic scenario 
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Case study   
Type I error control 
In this paper, we define Type I error as the probability of identifying a subgroup when there are 
no subgroups. When conducting an analysis using real data, it can be challenging to obtain Type 
I error control as if the analysis was conducted using simulated data. Hence, we implemented 
the permutation method for the analysis involving real data.  
Specifically, we break the association between treatment and covariate as well as between 
treatment and response; while keeping the association between covariate and response. In 
other words, we eliminated the predictive effect while keeping the prognostic effect. Other 
ways to control Type I error include the Šidák-based multiplicity adjustment method (Hochberg 
& Tamhane, 1987) as implemented in SIDES (Lipkovich, et al., 2011) and some more 
complicated permutation methods described in Foster et al (Foster, et al., 2016).  
Bootstrap 
In the analysis involving real data, one can easily obtain a naïve confidence interval for the point 
estimate of the treatment effect. However, such a confidence interval may not be valid because 
it does not take into consideration uncertainties from the selection of the predictive variable 
and the split value of the predictive variable. In the case study section of this paper, we 
implement a more complicated bootstrap method that is proposed by Loh et al (Loh, et al., 
2015) to obtain confidence intervals for the point estimate of the treatment effect.  
The bootstrap sample was drawn (with replacement) from the original dataset with the same 
size, and the VG method was applied. However, we ignored the identified signature based on 
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the bootstrap sample. Instead, we obtained newly predicted ITE, which are different from ITE 
predicted during the first step of VG method. The new ITE can be obtained directly from GUIDE. 
Then, by using the identified signature of the subgroup from the original dataset, the bootstrap 
sample can be separated into subgroups and the mean of new ITE for these subgroups can be 
obtained. After these procedures have been repeated B times (B = 500 in our case), the 
distribution and the confidence interval of the mean of new ITE for the identified subgroup can 
be obtained.  
Application 
We applied the VG method to a real world example from a clinical study evaluating an 
experimental treatment for patients with Alzheimer’s disease. The endpoint was the change 
from baseline to week 12 in ADAS-Cog 11 subscale score (0 to 70), which measures the change 
in severity of the disease. Thus, at the end of week 12, negative changes indicate improvement 
from baseline. There were two treatment arms: experimental treatment and placebo. In this 
case, the ITE for patient 𝑖 would be calculated as  
ITEi = 𝑦𝑖|𝑃𝑙𝑎𝑐𝑒𝑏𝑜, 𝑋𝑖 −  𝑦
′
𝑖
|𝑇𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡, 𝑋𝑖  
so that the larger the ITE, the better the treatment effect compared to placebo.  
We have included 17 covariates after consulting with medical professionals, including but not 
limited to age, sex, race, baseline Mini-Mental State Examination (MMSE, a disease staging 
measure, range 0 – 30), the change of ADAS-Cog 11 subscale score from screening to baseline, 
and Apolipoprotein E4 (APOE4).  
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Since there were total of three datasets in this project, and we needed to control the Type I 
error while analyzing the data. Thus, we followed the steps below to conduct the subgroup 
identification analysis on the first two datasets.  
1) Use permutation method on the first dataset to find the Type I error control; 
2) Analyze the first dataset while controlling the Type I error, identify the signature(s); and 
3) Find the subgroup in the second dataset according to the signature(s) identified in step 
2, and evaluate the treatment effect in the subgroup to see if it differs from the other 
subgroup.  
Unfortunately, when the Type I error was controlled at the 0.05 level, no subgroup was 
identified. Thus, we ignored Type I error control allowing for exploration of results that can be 
found. As shown in Figure 3, the covariate ‘Years Since Onset of the Symptom’ (YearOnset) was 
found as the predictive variable with a cut-off value at 3.55 years.  
Figure 3. Subgroup Identified From the First Dataset 
 
The cartoon in Figure 3 can be interpreted as follows (GUIDE reference): group ‘1’ contains the 
overall patient population from this dataset. The patients who satisfy the criteria ‘Years Since 
Onset of the Symptom ≤ 3.55 years’ are classified into subgroup ‘2’ (go along with the left line 
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to circle 2), otherwise, the patients are classified into subgroup ‘3’ (go along with the right line 
to circle 3).  
According to the result, subgroup ‘2’ had mean ITE = 1.24 with sample size 93, which means, on 
average, a larger treatment effect was observed in this subgroup of patients compared to the 
treatment effect observed in the rest of the patients (mean ITE = 0.24, n = 45). However, since 
Type I error was not controlled, we attempted to validate this result by observing the treatment 
effect in the subgroup of patients who were selected according to the identified signature 
(‘Years Since Onset of the Symptom ≤ 3.55 years) from the second dataset, and compared it 
with the treatment effect observed from the first dataset.  
Table 2. Estimated Treatment Effects 
Patient Group 
Estimated Treatment Effect 
First dataset Second dataset 
Overall 0.91 0.07 
YearOnset ≤  3.55 1.24 0.00 
YearOnset > 3.55 0.24 0.15 
 
As shown in Table 2, the observed treatment effect in the subgroups from the first dataset 
cannot be replicated in the subgroups from the second dataset by using the same signature. 
Therefore, the result obtained from the VG method was not valid in this case given there was 
no Type I error control.  
The third dataset in this project had a larger sample size than either of the first two datasets. 
Also, the experimental drug (Treatment) utilized in this dataset was different from the one 
utilized in the first two datasets. We applied the VG method on this dataset while controlling 
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the Type I error at 0.05, and one covariate was identified as the predictive variable with a cut-
off 20.  
Figure 4. Subgroup Identified From the Third Dataset 
 
As shown in Figure 4, subgroup ‘2’ was identified with a larger ITE compared to subgroup ‘3’, 
although subgroup ‘3’ had larger sample size. The identified covariate was MMSE, and the ITE 
appears to represent a clinically meaningful difference (Perneczky, et al., 2006). The cut-off value 
20 is suggested to be used as the separation of disease staging between moderate (≤20) and 
mild (>20). For this dataset, we have also calculated the 95% confidence interval in order to 
obtain an estimation of the validity of the results.  
Table 3. Estimated Treatment Effects and 95% CI 
Subgroup Mean Effect 95% CI 
MMSE ≥ 20 (group ‘2’) 1.09 (-0.11, 2.29) 
MMSE < 20 (group ‘3’) 0.24 (-1.19, 1.67) 
Difference between Above 
Two Subgroups 
0.85 (-0.79, 2.50) 
 
As shown in Table 3, although the treatment effect was numerically different from 0, the 95% 
confidence intervals for both subgroups contain 0. However, the 95% confidence interval in 
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subgroup ‘2’ is suggestive of a positive trend, while that in subgroup ‘3’ is not. Moreover, the 95% 
confidence interval for the difference of the treatment effects between the two subgroups is 
also suggestive of a positive effect favoring subgroup 2 over subgroup 3. Therefore, these 
results were felt to be clinically meaningful. Additional exploration (i.e., studies) may be 
necessary to demonstrate whether this is truly a clinically meaningful effect.  
Discussion 
Precision medicine attempts to improve the safety and/or efficacy of a drug by tailoring the 
treatment according to the patient’s characteristics. Subgroup identification is a critical step to 
realize the potential of precision medicine. However, current realizations of subgroup analysis 
in clinical trials are often limited within pre-defined subgroups. The current state of conducting 
analyses according to pre-defined subgroups while ignoring Type I error control may result in 
true predictive variable(s) and/or true cut-off value(s) being missed. Some data-mining based 
subgroup identification methods also exist. Most of these methods are used to prospectively 
search for subgroups given a dataset. By using data mining techniques, one can avoid pitfalls of 
common one variable at a time subgroup analyses.  
In this paper, we have proposed a novel method of prospective subgroup identification, the VG 
method, which combines the advantages of two existing methods (i.e., Virtual Twins and 
GUIDE). However, the VG method is not a simple combination of the two methods, it replace 
the CART part of the VT method by GUIDE. In other words, the VG method first calculates the 
Individual Treatment Effect (ITE) according to the counterfactual concept in causal inference; it 
then applies GUIDE to identify the subgroup(s) based on the ITE. Results from our simulation 
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studies show that the VG method outperforms Virtual Twins when there are binary and 
continuous covariates in the data and also outperforms GI when prognostic effect is as strong 
as predictive effect. The key advantage of the VG method compared to Gi is that it targets 
directly on the treatment effect and can identify a predictive variable in the presence of a 
prognostic effect. Also, the VG method has less potential for selection bias when compared to 
Virtual Twins given the latter’s reliance on CART. However, in our simulation, we have assumed 
there is only one predictive variable with one cut-off value due to the limitation of the tools we 
are using. In fact, there could be more than one predictive variable and there can be more than 
one cut-off value for a predictive variable in a given dataset.  
Through the case study, without Type I error control, the identified subgroup is not valid and 
the results cannot be reproduced. When the Type I error is controlled, although the identified 
subgroup is not statistically significant based on the 95% confidence intervals calculated using 
the bootstrap method, it demonstrates a trend related to the treatment effect that might be 
clinically meaningful. In other words, with conservatively controlled Type I error, the results 
might not be statistically significant, but might provide some clinically helpful information. In 
this case, additional research (i.e., clinical trials) would be needed to confirm this result. 
Our work has provided a clearly defined framework to compare three different subgroup 
identification methods according to type I error control, power and the conditional true 
discovery rate. It also provides two applications for controlling type I error and estimating 95% 
confidence intervals in the analysis of a real dataset, which are permutation and bootstrap 
methods, respectively. The performance of VG method relies on datasets, case by case 
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simulation is suggested to be tailored to the study. Generalization the conclusion to other 
studies should be careful. 
Our future work involves the improvement of the prediction accuracy when calculating the ITE, 
which is a critical factor that impacts the performance of the VG method. Moreover, we are 
trying to extend the VG method to both binary and time-to-event endpoints.   
Reference 
Dusseldorp, E. & Mechelen, I. V., 2014. Qualitative interaction trees: a tool to identify qualitative 
treatment-subgroup interaction. Statistics in Medicine, Volume 33, pp. 219-237. 
Foster, J. C. et al., 2016. Permutation Testing for Treatment–Covariate Interactions and Subgroup 
Identification. Statistics in Biosciences, 8(1), pp. 77-98. 
Foster, J. C., Taylor, J. M. & Ruberg, S. J., 2011. Subgroup Identification from Randomized Clinical Trial 
Data. Volume 30, pp. 2867-2880. 
Hochberg, Y. & Tamhane, A. C., 1987. Multiple Comparison Procedures. s.l.:Wiley. 
Lipkovich, I., Dmitrienko, A., Denne, J. & Enas, G., 2011. Subgroup identification based on differential 
effect search—A recursive partitioning method for establishing response to treatment in patient 
subpopulations. Volume 30, pp. 2601-2621. 
Loh, W.-Y., 2002. Regression trees with unbiased variable selection and interaction detection. Statistica 
Sinica, Volume 12, pp. 361-386. 
Loh, W.-Y., He, X. & Man, M., 2015. A regression tree approach to identifying subgroups with differential 
treatment effects. Statistics in Medicine, Volume 34, pp. 1818-1833. 
22 
 
Negassa, A. et al., 2005. Tree-structured subgroup analysis for censored survival data: Validation of 
computationally inexpensive model selection criteria. Statistics and Computing, Volume 15, pp. 231-239. 
Su, X. et al., 2009. Subgroup Analysis via Recursive Partitioning. Journal of Machine Learning Research, 
Volume 10, pp. 141-158. 
Su, X. et al., 2008. Interaction Trees with Censored Survival Data. The International Journal of 
Biostatistics, Jan, 4(1), p. 2. 
 
